-=Cardinal Health (CAH) reported earnings on Thur 3 May 2018 (b/o)

Cardinal Health misses by $0.12, reports revs in-line; slashes FY18 EPS guidance 

• Reports Q3 (Mar) earnings of $1.39 per share, excluding non-recurring items, $0.12 worse than the Capital IQ Consensus of $1.51; revenues rose 5.7% year/year to $33.63 bln vs the $33.48 bln Capital IQ Consensus.
• Co lowers guidance for FY18, sees EPS of $4.85-4.95 (Prior $5.25-5.50), excluding non-recurring items, vs. $5.42 Capital IQ Consensus Estimate.
  • This new guidance reflects the company's updated view on the performance of Cordis and its negative effect on the tax rate. The company will offer commentary for fiscal year 2019 during its earnings call today and expects to provide specific guidance when it reports year-end results in August.

=Cardinal Health (CAH) reported earnings on Thur 8 Feb 2018 (b/o)

Cardinal Health beats by $0.15, beats on revs; guides FY18 EPS above consensus 

• Reports Q2 (Dec) earnings of $1.31 per share, excluding non-recurring items, $0.15 better thanthe Capital IQ Consensus of $1.16; revenues rose 6.1% year/year to $35.19 bln vs the $34.63 bln Capital IQ Consensus.
• "Overall, we are very pleased with the quarter," said Mike Kaufmann, CEO of Cardinal Health. "Our Pharmaceutical Distribution business performed better than expected, and we continue to see strong growth in Specialty Solutions. In the Medical segment, the integration of the Patient Recovery business is progressing as planned, and we are excited by the opportunities in that business. In addition, we remain encouraged by how well our value proposition is resonating with customers... As we look to the remainder of the year," Kaufmann continued, "we anticipate our overall operating performance to be as expected."
• Co issues upside guidance for FY18, sees EPS of $5.25-$5.50, excluding non-recurring items, vs. $5.16 Capital IQ Consensus Estimate.  The guidance reflects $0.40 per share of benefit from the lower federal rate due to U.S. tax reform. 
• The Cardinal Health board of directors approved a new authorization to repurchase up to $1 billion of Cardinal Health common shares, which will expire on Dec. 31, 2020. With this new authorization, Cardinal Health is now authorized to repurchase up to $1.3 billion of its common shares. 

=Cardinal Health (CAH) reported earnings on Tue 7 Feb 2017 (b/o)

Cardinal Health beats by $0.10, misses on revs; lowers FY17 EPS, in-line :

• Reports Q2 (Dec) earnings of $1.34 per share, excluding non-recurring items, $0.10 better than the Capital IQ Consensus of $1.24; revenues rose 5.4% year/year to $33.15 bln vs the $33.58 bln Capital IQ Consensus. 
  • Second-quarter revenue for the Pharmaceutical segment increased 5% to $29.7 billion due to growth from existing Pharmaceutical Distribution customers and strong performance from the Specialty business. Segment profit for the quarter decreased 14% to $537 million. This decrease was driven by generic pharmaceutical pricing and, to a lesser extent, the previously announced loss of a large Pharmaceutical Distribution customer. This was partially offset by solid performance from Red Oak Sourcing.
  • Second-quarter revenue for the Medical segment increased 8% to $3.4 billion, driven by contributions from net new and existing customers. Segment profit increased 50% to $159 million due to the contribution from Cardinal Health Brand products, which includes Cordis. The increase reflects the $21 million unfavorable impact of the Cordis-related inventory fair value step-up in the second quarter of fiscal year 2016. Excluding this step-up, year-over-year Medical segment profit growth was 25%.
• Co issues in-line guidance for FY17, lowers EPS to $5.35-5.50 from $5.40-5.60, excluding non-recurring items, vs. $5.45 Capital IQ Consensus Estimate.

Cardinal Health (CAH) reported earnings on Mon 2 Nov 2015 (b/o)

** charts before earnings **

** charts after earnings **

Cardinal Health beats by $0.28, beats on revs; raises guidance for FY16, above consensus 

• Reports Q1 (Sep) earnings of $1.38 per share, excluding non-recurring items,$0.28 better than the Capital IQ Consensus of $1.10; revenues rose 16.6% year/year to $28.05 bln vs the $27.12 bln Capital IQ Consensus.
• Co raises guidance for FY16, sees EPS of $5.15-5.35, excluding non-recurring items, vs. $5.06 Capital IQ Consensus Estimate, up from $4.85-5.05.